BDX vs TMO
Becton Dickinson & Co. and Thermo Fisher Scientific Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BDX | TMO |
|---|---|---|
| Revenue | $21.8B | $44.6B |
| Net income | $1.7B | $6.7B |
| Gross margin | 45.4% | 57.1% |
| Net margin | 7.7% | 15.0% |
| Return on equity | 6.5% | 13.0% |
| Diluted EPS | $5.82 | $17.74 |
| Dividend / share | $4.16 | $1.72 |
| Payout ratio | 71.3% | 9.5% |
| Free cash flow | $2.7B | $6.3B |
| Equity | $25.4B | $53.4B |
| Net debt / equity | 0.73× | 0.62× |
| Current ratio | 1.11× | 1.89× |
| Revenue CAGR 5y | 6.3% | 6.7% |
| Profit CAGR 5y | 13.9% | 1.0% |
TMO bills 2.0× the revenue of BDX, and keeps more of each dollar of revenue as profit (15.0% against 7.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | BDX | TMO |
|---|---|---|
| FY2025 | $21.8B | $44.6B |
| FY2024 | $20.2B | $42.9B |
| FY2023 | $19.4B | $42.9B |
| FY2022 | $18.9B | $44.9B |
| FY2021 | $19.1B | $39.2B |
| FY2020 | $16.1B | $32.2B |
| FY2019 | $17.3B | $25.5B |
| FY2018 | $16.0B | $24.4B |
| FY2017 | $12.1B | $20.9B |
| FY2016 | $12.5B | $18.3B |
Net income by year
Bottom line
| Fiscal year | BDX | TMO |
|---|---|---|
| FY2025 | $1.7B | $6.7B |
| FY2024 | $1.7B | $6.3B |
| FY2023 | $1.5B | $6.0B |
| FY2022 | $1.8B | $7.0B |
| FY2021 | $2.1B | $7.7B |
| FY2020 | $874.0M | $6.4B |
| FY2019 | $1.2B | $3.7B |
| FY2018 | $311.0M | $2.9B |
| FY2017 | $1.1B | $2.2B |
| FY2016 | $976.0M | $2.0B |
Advertisement
AdSense · Rectangle 336×280